Diabetic Neuropathy Market, By Disorder Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy), By Treatment Type (Drugs, Analgesic, Antidepressants, Anticonvulsant Drugs, Radiotherapy and Physiotherapy), By Distribution Channel (Hospitals, Clinics, Retail Pharmacy, Online Pharmacy), Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Trends, Analysis and Forecast till 2030

The market for diabetic neuropathy was valued at US$4.22 billion in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 8.90% to reach US$9.87 billion by 2030.

Diabetic neuropathy is the term used to describe the damage that diabetes causes to nerves, resulting in numbness and discomfort that is typically felt in the lower body, such as the legs and feet. This is a frequent side effect of type 1 and type 2 diabetes, affecting the nerves in the thigh, wrist, chest, back, etc. Diabetes for an extended period, kidney illness, poor blood sugar management, obesity, smoking, and nerve damage are among the variables that contribute to this syndrome. However, neuropathy can strike anyone with diabetes. Pain, tingling, numbness, and loss of feeling in the hands, arms, feet, and legs are a few signs of diabetic neuropathy. Diabetic neuropathy can be treated with medications, physical therapy, and radiation.